• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Reed-Lane

    Syngene

    Adare Pharma Solutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Alcami

    PCI Pharma Services

    Adare Pharma Solutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Good Clinical Practice: Serious Breach Process

    How to assess the significance of the breach, who needs to be involved, and how to report it

    Good Clinical Practice: Serious Breach Process
    Related CONTENT
    • Trial Runners
    • SGS Life Sciences
    • PharmaServe
    • Celldex Therapeutics Appoints CMO
    • Bellwyck Pharma Services on Growth Path
    Jane Wood, Principal, YourEncore Quality Center of Excellence06.27.19
    There is nothing more important than patient and consumer safety. At the end of the day, the importance of safety lies in all that development teams do: the drugs, devices and products they produce. There are so many ways of ensuring patient safety. There are regulations, protocols, well-trained staff, validated IT systems etc., but a necessarily important concept to review is the serious breach process.

    What is a serious breach? It is a breach of a clinical trial protocol that is likely to affect, to a significant degree, the safety (both physical and mental) and rights of a subject or the reliability, robustness or scientific value of data generated in a clinical trial. Deviations from protocols and GCP commonly occur in clinical trials, the vast majority of which are minor deviations that do not result in harm to the trial subjects or affect the data outcomes. In these cases, teams follow the normal process of documenting the deviation and taking the appropriate corrective and preventative actions. However, when the deviation is more serious, teams need to know how to handle the situation, how to assess the significance of the breach, who needs to be involved, and how to report it.

    As FDA regulations report, adherence to the principles of GCP is universally accepted as a critical requirement to the conduct of research involving human subjects.In the US, there is no specific regulation discussing serious breaches per se, however all the regulations point to the essential requirement of human subject protection and handling of non-compliance. In Europe, the regulations are more specific; EU No 536/2014 states, “The sponsor shall notify the member states concerned about a serious breach or of the version of the protocol applicable at the time of the breach through the EU portal without undue delay, but not later than 7 days after becoming aware of that breach.” Although there is delay in the implementation of the EU portal, it is still an expectation that teams follow the serious breach process. In the ICH E6(R2) Addendum, section 5.20 (Non-compliance), it reads “5.20.1 If noncompliance that significantly affects or has the potential to significantly affect human subject protection or reliability of trial results is discovered, the sponsor should perform a root cause analysis and implement appropriate corrective and preventive actions.”

    Every sponsor needs a serious breach process, and the outlined details are vital to each situation’s success:

    ·       Document your process in a Policy or SOP. If you don’t have a documented process, it most likely will be a Health Authority inspection finding. Include who owns the serious breach investigation process, who should attend, who makes the decisions, how do you escalate, who reports. In your process. You may also want to “Charter” the constitution of the serious breach committee. However you decide to document the process, it should be formal and include receipt, assessment, investigation, escalation, Corrective and Preventative Actions (CAPA) and reporting to the HA(s).

    ·       When should a breach be reported to the Health Authority (HA)?Any breach should be reported within seven calendar days of the sponsor, or anyone who has contractual agreements with the sponsor (e.g. vendors, suppliers, CROs), becoming aware of the breach. This means that you need to clearly define Day 0; this is the first awareness at the clinical trial site or when the sponsor or CRO become aware.

    ·       Sponsor oversight is a critical element of ICH GCP. Make sure you document, in the contract or other documented communications with your vendors, when they must report non-compliances or serious breaches to the sponsor.

    ·       What happens if the breach needs significant and lengthy investigation?It is important to report first and then continue to investigate the details, which can be provided later to the HA. When reporting, consider who else externally needs to be notified, i.e. the Investigation Review Board (Ethics Committee). If the clinical trial is halted, what other regulatory notifications need to be made?

    ·       When you first start a serious breach process, expect over-reporting. This is normal; it might take a while before you hit the true level of reporting. It’s also pertinent to look at incidences that come close to a serious breach definition. This way you can potentially avoid a non-compliance situation down the line.

    ·       The serious breach assessment itself should follow your Quality Management System (QMS). The investigation should be prompt, and you must perform a root cause analysis and assess the impact on the scientific value of the data, as well as the impact on patient safety. Once the root cause is known, then it should follow your routine CAPA system.

    ·       It is safe to assume most cases of fraud are a serious breach. It’s okay to merge these two types of investigations together in the Policy or SOP.

    ·       Consider also tying together the serious breach with your protocol deviation review process. You should define at what stage a multitude of minor deviations become a serious breach. The team should also recognize the strong relationship between safety signal detection and the serious breach process.

    ·       A serious breach investigation must be documented and held for inspection. It must be retained for 25 years in the Trial Master File, but it’s a good idea to also keep a separate log of incidences ready for inspection. Remember, serious breaches also go in the Pharmacovigilance System Master File (PSMF).

    ·       It is useful to circulate the serious breach to relevant internal stakeholders so that it may be included in the Clinical Study Report or publications. It must also feed into the QMS and be captured at relevant management reviews to ensure it doesn’t reoccur.

    In formulating a serious breach process, sponsors should not underestimate the significant effort required for staff training to create staff awareness and understanding. The time spent on training and awareness now could prevent increasing time and cost demands down the line. For more useful regulation examples, reference the end of EU No 536/2014. A consistent serious breach process can lead to better patient safety and precise data.



     
    Building on 40 years of industry and leadership experience, Jane brings a wide range of Quality & Compliance experience to YourEncore, tailoring Quality Management Systems aligning with ICH E6 (R2) and other regulations, developing strategies for weaving the business and R&D quality together, consulting on R&D quality and compliance issues. Jane specializes in helping prepare for, mitigate, and resolve global Regulatory actions, including mock inspections, assessments and audits. Jane most recently led the R&D Quality & Compliance function for Johnson & Johnson, leading a global team of 360 colleagues with broad-based GXP compliance responsibilities across the Pharmaceutical, Medical Device, and Consumer sectors.
    Related Searches
    • pharmacovigilance
    • fda
    • Clinical Trials
    • Clinical Trial
    Suggested For You
    Trial Runners Trial Runners
    SGS Life Sciences SGS Life Sciences
    PharmaServe PharmaServe
    Celldex Therapeutics Appoints CMO Celldex Therapeutics Appoints CMO
    Bellwyck Pharma Services on Growth Path Bellwyck Pharma Services on Growth Path
    Cognate Compliant with EU GMPs Cognate Compliant with EU GMPs
    Cytek Biosciences Achieves ISO 9001:2015 certification Cytek Biosciences Achieves ISO 9001:2015 certification
    Are Biotech Companies Strong Investments? Are Biotech Companies Strong Investments?
    Financial Report: Mylan Financial Report: Mylan
    Financial Report: Sanofi Financial Report: Sanofi
    Mallinckrodt Completes Wisconsin Mfg. Facility Mallinckrodt Completes Wisconsin Mfg. Facility
    Indena SpA Indena SpA
    SomaLogic & Janssen Enter Agreement SomaLogic & Janssen Enter Agreement
    Industry 4.0 in the Pharma Industry Industry 4.0 in the Pharma Industry
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?

    Related Expert's Opinion

    • Clinical Trials | Information Technology
      Data Management Trends

      Data Management Trends

      Pandemic-fueled patient centricity is creating new challenges and opportunities for data management teams.
      Deepu Joseph, Global Head & VP of Clinical Data Management 03.05.21

    • Clinical Trials | Information Technology
      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Look for a future-proof model, innovative vendors - not cutting-edge technology, and focus on user-centered design and interoperability.
      Andres Garcia, Co-founder and CTO Florence 02.08.21

    • Clinical Trials
      The Future of Clinical Trials Series: Part II

      The Future of Clinical Trials Series: Part II

      Greater awareness will ensure diversity is no longer an afterthought and patients will be at the center of every aspect of clinical research.
      Jena Daniels, Rasmus Hogreffe, Ingrid Oakley-Girvan, Dr. Michelle Longmire, Medable 01.26.21


    • Clinical Trials
      The Future of Clinical Trials Series: Part I

      The Future of Clinical Trials Series: Part I

      What will 2021 have in store for an industry in flux?
      Alison Holland, Head of Decentralized Trials, Medable, Maria Fotiu, Executive Vice President of Decentralized Solutions, Syneos Health 01.19.21

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21


    • Clinical Trials | Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown, SVP of Integrated Technology & Compliance, and Joe Rymsza, VP, Global PV & Regulatory Technology Solutions, IQVIA 12.14.20

    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Clinical Trials | Information Technology
      AI and Advanced Analytics

      AI and Advanced Analytics

      Equipped with the right tools, CROs are better positioned to develop optimal protocols, rapidly identify patients to enroll, and preempt study issues.
      Paul Oliver, Medidata 11.13.20


    • Clinical Trials | Information Technology
      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      Clinical Outcome Assessments are an increasingly important tool in clinical research.
      Paul O'Donohoe, Scientific Lead, eCOA and Mobile Health, Medidata 11.13.20

    • Clinical Trials | Information Technology
      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Traditional monitoring has changed, CROs should build a portfolio of remote access solutions and have them ready.
      Ryan Jones, CEO, Florence Healthcare 10.13.20

    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20


    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Avacta’s Rapid Antigen Test Proves Effective for New Coronavirus Variants
    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Jubilant Therapeutics Appoints Chief Scientific Officer
    Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    Vetter Establishes Office in China
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Ulta Beauty Opens in Herald Square
    Happi

    Latest Breaking News From Happi

    Batiste Rolls Out Wonder Woman Dry Shampoo
    Erno Laszlo Taps Carina Lau as Global Spokesperson
    It's International Women's Day
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson reveals new ink for ColorWorks C6000-Series label printers
    VPF launches liner made from recycled paper
    Cartes engineers inkjet embellishment technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login